What is the practical difference between drostanolone enanthate and drostanolone propionate esters?

The key difference is release duration and injection frequency. Drostanolone enanthate carries a longer carbon chain, releasing the parent hormone over approximately 10–11 days, which allows twice-weekly injections. Propionate has a 2–3 day active window, requiring every-other-day dosing to maintain stable blood levels. Both deliver identical pharmacodynamic effects — only the pharmacokinetic profile differs.

Which drostanolone ester form is better suited for a 12-week structured cycle?

Drostanolone enanthate is generally preferred for cycles of 10 weeks or longer because its extended half-life stabilises serum androgen levels with fewer injections and allows the compound to reach steady-state concentration within roughly two weeks of starting. Propionate achieves faster onset but demands more frequent administration, making it more practical for shorter, tightly managed runs where rapid clearance is a priority.

How does injectable oil-based drostanolone differ from oral or transdermal forms of administration?

Intramuscular oil-based injection bypasses first-pass hepatic metabolism entirely, delivering the active molecule directly into systemic circulation via tissue absorption — a route that offers higher bioavailability than any oral drostanolone form (which faces significant liver breakdown). Transdermal drostanolone exists experimentally but lacks consistent absorption data. The injectable oil depot also acts as a controlled-release reservoir that neither oral nor transdermal delivery replicates.

Why is 250 mg/ml a meaningful concentration for drostanolone enanthate, and how does it affect injection volume?

At 250 mg/ml, Drostan-E provides 25 mg more active compound per millilitre than standard 200 mg/ml formulations. A typical 500 mg weekly dose requires only 2 ml total, split into two 1 ml injections — reducing per-site volume and associated tissue stress compared to the same dose from a lower-concentration vial. This matters for users stacking multiple compounds and managing total injection volume per session.

How should the Drostan-E 10ml vial be stored after opening, and how many doses does it typically provide?

After the rubber stopper is first punctured, the vial should be stored at room temperature (15–25°C), away from direct light, and used within 28 days. Refrigeration is not required but helps preserve preservative efficacy. At 250 mg/ml, a 10 ml vial contains 2,500 mg total — equivalent to roughly 10 weekly doses of 250 mg or 5 weekly doses of 500 mg, making it practical for a full 5–10 week supply in a single vial. (2) angle_used

Established Brand

GenTec

Drostan-E 250mg/ml 10ml Vial by GenTec

Name: Drostan-E 250mg/ml 10ml Vial by GenTec
Brand: GenTec
SKU: INJ-DROE-GEN-250-005
Price: 46.00 EUR
Availability: InStock

Drostan-E by GenTec delivers drostanolone enanthate at 250 mg/ml — the highest concentration available in this class — as a long-acting injectable whose enanthate ester fundamentally extends active-release duration, enabling a reduced injection schedule while maintaining stable androgen levels across structured cycle protocols. Understanding ester selection is central to practical cycle design: the enanthate variant suits longer, less-frequent dosing frameworks, whereas shorter esters demand more injections to sustain comparable serum presence. HPLC-verified batch concentration and LAL endotoxin testing are applied per vial lot, with each certificate of analysis cross-referenced against stated label values before product release.

€46.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

250 mg/ml concentration reduces total injection volume per weekly dose compared to standard 200 mg/ml products
Enanthate ester sustains active drostanolone release across an approximately 10–11 day window
Twice-weekly injection schedule replaces the every-other-day regimen required by propionate formulations
HPLC-verified batch concentration ensures each millilitre delivers the declared active compound amount
LAL endotoxin testing per lot confirms sterility independently of concentration assay
Single-ingredient formulation allows precise ester-matched stacking with other long-ester compounds
Multi-dose 10 ml vial format accommodates a full 5–10 week supply within a single container

Phase	Dosage	Note
Introductory (Weeks 1–2)	250 mg/week (1 ml × 1 injection/week)	Allows assessment of individual response during enanthate ester build-up phase; single weekly injection acceptable while serum levels are still rising toward steady state
Maintenance / Main Cycle (Weeks 3–12)	400–500 mg/week (0.8–1 ml twice weekly, e.g. Mon/Thu)	Twice-weekly split exploits enanthate ester's release profile to minimise peak-to-trough variation; at 250 mg/ml, 500 mg/week = 2 ml total per week (1 ml per injection)
Ester Washout (Post-last Injection)	No active dosing	Allow approximately 14 days before initiating PCT to account for the enanthate ester's extended clearance time — significantly longer than the 3–5 day clearance required after propionate

Key takeaways

Choose enanthate over propionate when reducing injection frequency matters.
Confirm ester type before planning weekly dosing intervals.
Leverage 250 mg/ml concentration to minimise per-injection oil volume.
Verify HPLC batch documentation to ensure labelled concentration accuracy.
Schedule twice-weekly injections to sustain stable enanthate serum levels.

Drostanolone Enanthate vs. Drostanolone Propionate: Understanding the Ester Difference

Drostan-E is a single-compound injectable formulation of drostanolone bonded to the enanthate ester, concentrated at 250 mg/ml in a 10 ml multi-dose vial — a product whose clinical relevance begins with understanding how ester selection alters the pharmacokinetic profile of an otherwise identical parent molecule. The enanthate ester extends the parent compound's release window to approximately 10–11 days, compared to 2–3 days for the propionate form; this difference is not minor — it determines injection frequency, serum stability, and practical cycle architecture. GenTec produces Drostan-E under conditions where HPLC analysis confirms that stated concentration matches filled concentration before distribution.

How Ester Length Shapes Practical Administration

Longer-chain esters slow diffusion from the oil depot into surrounding tissue, delaying enzymatic processing of the ester bond and thereby sustaining plasma availability over an extended timeframe. Drostanolone enanthate achieves this through the seven-carbon enanthate chain, which holds the parent molecule in lipophilic suspension longer than the two-carbon propionate chain can. The practical consequence: twice-weekly injection intervals (e.g., Monday/Thursday) are sufficient with the enanthate form to maintain consistent androgen exposure, whereas propionate conventionally requires every-other-day or three-times-weekly administration to prevent troughs. For users who prioritise injection convenience without sacrificing androgen consistency, the enanthate ester represents a meaningful pharmacokinetic upgrade compared to propionate at equivalent weekly milligram totals.

Concentration, Dosage Form, and Administration Considerations

At 250 mg/ml, Drostan-E carries a higher concentration per millilitre than standard 200 mg/ml drostanolone enanthate products, which affects injection volume per dose: a 500 mg weekly dose requires only 2 ml total volume (divided across two injections of 1 ml each), reducing tissue burden at any single site. The oil-based multi-dose vial format is compatible with standard 23–25 gauge intramuscular injection technique into gluteal, lateral quadriceps, or deltoid sites. Each batch undergoes LAL (Limulus Amebocyte Lysate) endotoxin testing in addition to HPLC concentration verification, providing two independent quality checkpoints per lot. GenTec's documented batch-release protocol requires both assay results to meet specification before a vial lot is cleared for distribution.

Usage

Select injection site appropriate for intramuscular oil-based administration (gluteus maximus, vastus lateralis, or deltoid); rotate sites across each injection to prevent scar tissue accumulation over a multi-week cycle.
Use a 23–25 gauge, 1–1.5 inch needle for intramuscular injection; draw with a larger-gauge needle if desired, then swap to the finer gauge for administration to reduce tissue trauma.
Warm the vial briefly to body temperature (hold in palm for 60 seconds) to reduce oil viscosity and ease injection, particularly relevant at 250 mg/ml where the solution may be thicker than lower-concentration formulations.
Inject slowly over 30–60 seconds; rapid oil injection increases local pressure and post-injection discomfort — especially pertinent with a denser 250 mg/ml preparation.
Space injections to align with the enanthate ester's release profile — a Monday/Thursday schedule provides consistent androgen delivery without the every-other-day regimen associated with the propionate ester form.
After opening, use the vial within 28 days; discard if the solution appears cloudy, discoloured, or shows visible particulate matter — consult the batch COA to confirm expected appearance and concentration.

Warnings

Contraindications: Drostan-E is contraindicated in individuals with androgen-sensitive malignancy (including prostate and male breast carcinoma), active cardiovascular disease, or documented hypersensitivity to drostanolone or any component of the oil-based carrier. Women who are pregnant or may become pregnant must not use this product. Individuals under 21 years of age should not administer anabolic-androgenic steroids.

Side Effects: Androgenic adverse effects include accelerated androgenetic alopecia in genetically predisposed users, acne vulgaris, and increased sebaceous gland activity. Drostanolone does not aromatise, eliminating oestrogen-mediated side effects such as gynaecomastia; however, it may suppress endogenous testosterone synthesis in a dose- and duration-dependent manner. Lipid profile disruption — specifically suppression of HDL cholesterol — is a documented cardiovascular risk requiring monitoring, particularly during cycles extending beyond 10 weeks.

Monitoring: Baseline and on-cycle blood work should include total testosterone, LH, FSH, haematocrit, and a lipid panel (HDL/LDL ratio). Liver enzyme panels (ALT/AST) are advisable, though drostanolone is not 17-alpha-alkylated and hepatotoxicity risk is substantially lower than with oral androgens. Blood pressure monitoring is recommended throughout the cycle.

PCT: Because the enanthate ester takes approximately 14 days to clear after the final injection — compared to 4–5 days for propionate — post-cycle therapy (PCT) initiation should be delayed accordingly. Standard PCT protocols employing selective oestrogen receptor modulators (SERMs such as tamoxifen or clomiphene) should begin only after the ester clearance window has elapsed to avoid pharmacokinetic interference with endogenous axis recovery.

Frequently asked questions

What is the practical difference between drostanolone enanthate and drostanolone propionate esters?: The key difference is release duration and injection frequency. Drostanolone enanthate carries a longer carbon chain, releasing the parent hormone over approximately 10–11 days, which allows twice-weekly injections. Propionate has a 2–3 day active window, requiring every-other-day dosing to maintain stable blood levels. Both deliver identical pharmacodynamic effects — only the pharmacokinetic profile differs.
Which drostanolone ester form is better suited for a 12-week structured cycle?: Drostanolone enanthate is generally preferred for cycles of 10 weeks or longer because its extended half-life stabilises serum androgen levels with fewer injections and allows the compound to reach steady-state concentration within roughly two weeks of starting. Propionate achieves faster onset but demands more frequent administration, making it more practical for shorter, tightly managed runs where rapid clearance is a priority.
How does injectable oil-based drostanolone differ from oral or transdermal forms of administration?: Intramuscular oil-based injection bypasses first-pass hepatic metabolism entirely, delivering the active molecule directly into systemic circulation via tissue absorption — a route that offers higher bioavailability than any oral drostanolone form (which faces significant liver breakdown). Transdermal drostanolone exists experimentally but lacks consistent absorption data. The injectable oil depot also acts as a controlled-release reservoir that neither oral nor transdermal delivery replicates.
Why is 250 mg/ml a meaningful concentration for drostanolone enanthate, and how does it affect injection volume?: At 250 mg/ml, Drostan-E provides 25 mg more active compound per millilitre than standard 200 mg/ml formulations. A typical 500 mg weekly dose requires only 2 ml total, split into two 1 ml injections — reducing per-site volume and associated tissue stress compared to the same dose from a lower-concentration vial. This matters for users stacking multiple compounds and managing total injection volume per session.
How should the Drostan-E 10ml vial be stored after opening, and how many doses does it typically provide?: After the rubber stopper is first punctured, the vial should be stored at room temperature (15–25°C), away from direct light, and used within 28 days. Refrigeration is not required but helps preserve preservative efficacy. At 250 mg/ml, a 10 ml vial contains 2,500 mg total — equivalent to roughly 10 weekly doses of 250 mg or 5 weekly doses of 500 mg, making it practical for a full 5–10 week supply in a single vial. (2) angle_used

Manufacturer

GenTec's quality infrastructure for Drostan-E centres on two analytically distinct release checkpoints applied to each finished batch before market distribution: HPLC (High-Performance Liquid Chromatography) concentration assay and LAL (Limulus Amebocyte Lysate) endotoxin testing. The HPLC assay quantifies actual drostanolone enanthate concentration against the declared 250 mg/ml label figure — converting a nominal specification into a documented, measurable result tied to the specific lot. LAL endotoxin testing operates independently, screening each batch for bacterial endotoxin contamination that standard visual inspection cannot detect. Both assay results are captured in a per-batch certificate of analysis that GenTec maintains as part of its traceability documentation, providing downstream verification that the vial a user receives reflects a product that has cleared two independent quality gates rather than one.

Product details

Brand	GenTec
Active ingredient	drostanolone enanthate
Also known as	Masteron Enanthate, Drostanolone Enanthat, Drostan-E, GenTec Masteron Enanthate
Strength	250 mg
Form	Vial
Pack size	1 piece
Item number	INJ-DROE-GEN-250-005

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

High Concentration

Etho-Masteron 200mg/ml 10ml Vial by Beligas Pharmaceuticals

Etho-Masteron by Beligas Pharmaceuticals is a high-concentration injectable Drostanolone Enanthate solution, dosed at 200mg/ml in a 10ml vial, engineered to integrate cleanly into structured, periodized cycle protocols where sustained androgenic support is the primary objective. The extended-release enanthate ester makes it particularly well-suited to modern cutting and recomposition blueprints that demand stable hormone levels over multi-week blocks without frequent injection windows. Batch release is governed by HPLC chromatographic quantification against certified reference standards; sterility is confirmed via LAL endotoxin assay — both conducted under GMP-compliant production conditions at Beligas Pharmaceuticals.

€54.00

Masten-200 200mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Masten-200 200mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Masten-200 is a long-chain ester injectable delivering Drostanolone Enanthate at 200 mg/ml across ten single-dose glass ampoules, distinguished by its extended pharmacokinetic profile — a half-life of approximately 10–11 days that enables stable plasma concentrations between infrequent administrations. The enanthate ester slows enzymatic cleavage of the parent hormone, sustaining active Drostanolone release across a broad time window rather than producing the sharp peak-and-trough pattern of shorter ester variants. Each batch undergoes HPLC-verified potency confirmation and LAL endotoxin testing; sterile fill integrity is independently validated before release by BM Pharmaceuticals.

€55.00

Brand Quality

Masteron 200 200mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma Masteron 200 is an oil-based injectable delivering Drostanolone Enanthate at 200 mg/ml in a 10 ml vial, formulated specifically to support structured cruise-and-blast programming where androgenic density must shift between maintenance and growth phases without changing compounds. The long-acting enanthate ester sustains active hormone levels across the full blast window and remains pharmacokinetically compatible during reduced-dose cruise intervals. Each production batch of Masteron 200 is manufactured inside a GMP-certified facility; finished vials are HPLC-quantified against a certified Drostanolone reference standard and LAL-tested for endotoxin clearance before batch release.

€48.00

Pro Choice

Drostargos 200mg/ml 10ml Vial by Driada Medical

Drostargos is a long-acting injectable androgen from Driada Medical, delivering 200 mg of Drostanolone Enanthate per millilitre across a 10 ml multi-dose vial — formulated specifically to serve men over 40 pursuing hormone optimisation and anti-aging body-composition goals alongside or adjacent to testosterone replacement therapy. Its extended-release enanthate ester sustains stable androgenic activity across the week, making twice-weekly administration practical without sharp hormonal fluctuations that complicate quality-of-life management in older users. HPLC quantification of the active content and LAL endotoxin screening are completed at GMP Standard batch release; the resulting analytical certificate travels with each vial lot.

€56.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00